Register
Community
Overview
Experts
Editors
Fellows
Code of conduct
Company
About Us
FAQs
Privacy Policy
Terms of Use
Careers
Programs
News
News Releases
Press Coverage
Publications
Blog
Contact Us
Sign in
Pulmonology
Breast Cancer
Questions discussed in this category
Would you start any treatment for radiation pneumonitis if there is a large area of consolidation in the irradiated lung field but the patient is asymptomatic?
Would you consider pentoxifylline and vitamin E to mitigate fibrosis?
2 Answers available
Would you give T-DXd to patients with resolved drug-induced ILD from other agents such as prior chemo/targeted therapy/immunotherapy?
2 Answers available
How do you monitor for pulmonary toxicity for patients on trastuzumab deruxtecan?
Would you obtain baseline PFT on all patients or only selected high risk patients? Would you repeat PFTs regularly or only if clinically symptomatic?&...
5 Answers available
What strategies can be employed to manage interstitial lung disease seen with trastuzumab deruxtecan?
Can patients be re-challenged after developing ILD? Is the toxicity seen with T-Dxd a potential barrier to use? Do you feel the dosing used in...
2 Answers available
18770
16523
7725
11167
Papers discussed in this category
Cancer Treat Rev, 2022 Mar 12
Multidisciplinary clinical guidance on trastuzumab deruxtecan (T-DXd)-related interstitial lung disease/pneumonitis-Focus on proactive monitoring, diagnosis, and management.
Related Topics in Pulmonology
Lung Cancer
Breast Cancer
Head and Neck Cancers
Hematologic Malignancies
Radiation Oncology
Gynecologic Cancers
Palliation
Neuro-Oncology
Gastrointestinal Cancers
Melanoma/Skin Cancer